Duke Translational Medicine Institute, Durham, North Carolina 27710, USA.
Acad Med. 2010 Mar;85(3):457-62. doi: 10.1097/ACM.0b013e3181ccb74d.
A comprehensive system for translating basic biomedical research into useful and effectively implemented clinical diagnostic, preventive, and therapeutic practices is essential to the nation's health. The state of clinical and translational research (CTR) in the United States, however, has been characterized as fragmented, slow, expensive, and poorly coordinated. As part of its Roadmap Initiative, the National Institutes of Health instituted the Clinical and Translational Science Awards (CTSA), a sweeping and ambitious program designed to transform the conduct of biomedical research in the United States by speeding the translation of scientific discoveries into useful therapies and then developing methods to ensure that those therapies reach the patients who need them the most. The authors review the circumstances of the U.S. biomedical research enterprise that led to the creation of the CTSA and discuss the initial strategic plan of the CTSA, which was developed from the first three years of experience with the program and was designed to overcome organizational, methodological, and cultural barriers within and among research institutions. The authors also describe the challenges encountered during these efforts and discuss the promise of this vital national health care initiative, which is essential to creating a pipeline for the scientific workforce needed to conduct research that will, in turn, provide a rational evidence base for better health in the United States.
将基础生物医学研究全面转化为有用且能有效实施的临床诊断、预防和治疗实践,这对国家的健康至关重要。然而,美国的临床和转化研究(CTR)状况一直呈现碎片化、缓慢、昂贵和协调不良的特点。作为其路线图倡议的一部分,美国国立卫生研究院(NIH)启动了临床和转化科学奖(CTSA),这是一个全面而雄心勃勃的计划,旨在通过加速将科学发现转化为有用的疗法,从而改变美国生物医学研究的实施方式,然后开发方法以确保这些疗法能够到达最需要的患者手中。作者回顾了导致 CTSA 成立的美国生物医学研究企业的情况,并讨论了 CTSA 的初始战略计划,该计划是根据该计划头三年的经验制定的,旨在克服研究机构内部和之间的组织、方法和文化障碍。作者还描述了在这些努力中遇到的挑战,并讨论了这一重要的国家医疗保健计划的前景,这对于为开展研究所需的科学劳动力建立一个渠道至关重要,而开展研究反过来又将为美国提供更好的健康提供合理的证据基础。